Sanofi launches trial for 2nd COVID-19 vaccine candidate

Sanofi has begun a phase 1/2 human trial for the mRNA COVID-19 vaccine candidate it is developing with Lexington, Mass.-based mRNA therapeutics company Translate Bio, the companies announced March 12.

Sanofi expects the trial to enroll 415 participants, with interim results slated for 2021's third quarter. The trial will test the vaccine's safety, tolerability and immune response.

The drugmaker said preclinical data for the vaccine demonstrated high neutralizing antibody levels. It also said it is working on preclinical trials to test additional mRNA candidates against coronavirus variants.

Sanofi launched a different clinical trial Feb. 22 for the protein-based COVID-19 vaccine candidate it is developing with GlaxoSmithKline. Sanofi and GlaxoSmithKline expect the vaccine to become available in 2021's fourth quarter.

More articles on pharmacy:
Eli Lilly says its COVID-19 antibody cocktail reduces hospitalization, death risk by 87%
Pfizer vaccine blocks 94% of asymptomatic cases in Israeli study
Novavax says its COVID-19 vaccine is 96% effective against original virus strain


Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Learning Opportunities

Featured Whitepapers

Featured Webinars